News | July 10, 2024
Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Dr. Sanjay Behari, Director of Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, as the President of the Medical Assessment and Rating Board
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
Berlinger brings a suite of proprietary and high-quality hardware and software solutions that broaden Sensitech's end-to-end cold chain monitoring product portfolio
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Nadda also interacted with senior officials of the Union Health Ministry after taking charge where he was briefed about the ongoing projects
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
Subscribe To Our Newsletter & Stay Updated
